How R&D Teams Create Value from On-Market Products
Most pharma R&D organisations are defined and measured by how well they deliver new product innovation, which is often a high risk, high return endeavour. Yet such companies almost always have a second, highly important and sometimes underappreciated role: creating value from on-market products. Some companies even avoid new product innovation entirely, but still have […]
How to Power Pharma and Biotech R&D with Sharp Commercial Insights
Pharmaceutical research and development (R&D) organisations and pre-revenue biotechs aim to discover and develop medicines that will make a meaningful difference to patients’ lives. Such medicines will be those that are ‘commercially’ successful, so ‘commercial insight’ is a must-have for any effective R&D effort. In this article we explore how pharma and biotech companies leverage […]
The Novasecta European MidPharma Report 2022
Europe is home to 97 ‘MidPharmas’ – companies that develop and commercialise pharmaceutical products, with €100m-€6bn annual revenue. In our seventh annual report into this sector, we examine how these companies thrive, explore the key lessons similar organisations can learn, and conclude with imperatives for the entire pharmaceutical and biotech ecosystem. What To Expect In […]
How European MidPharmas have Grown Profits (MedNous)
Europe is home to 85 mid-sized pharmaceutical companies (MidPharmas) that invest in developing and commercialising pharmaceutical products. Many of these companies have achieved impressive, upward-trending earnings before interest and tax (EBIT) margins in the last five years. The median EBIT margin of MidPharma is now comparable to that of the largest pharma companies and many […]
How Pharma Manages Organisational Complexity
The success of large pharmaceutical companies hinges on their ability to deliver innovative therapies to patients, which drives them to grow and diversify their portfolios. With more scale and diversity, organisational structures and decision-making processes become more complex. Pharma leaders can navigate organisational complexity in many ways, but two constants persist: maintaining a strategic focus […]
How European MidPharmas have Grown Profits
Europe is home to 85 mid-sized pharmaceutical companies (MidPharmas) that invest in developing and commercialising pharmaceutical products. Many of these companies have achieved impressive, upward-trending earnings before interest and tax (EBIT) margins in the last five years. The median EBIT margin of MidPharma is now comparable to that of the largest pharma companies and many […]
Five Imperatives For Strategic And Operational Excellence
As technological advances and competition in the pharmaceutical ecosystem accelerate, it is vital for companies to stay at the cutting edge. The leading pharmaceutical companies focus, move fast and move together. They embrace strategic and operational excellence. Why is strategic and operational excellence important? Pharmaceutical and biotech companies must optimise the effectiveness of the multiple […]
The Art of Effective R&D Transformation
Productive R&D is the lifeblood of leading pharmaceutical and biotech companies, and with increased pressure to create meaningful new medicines, R&D effectiveness can always be improved. In our recent webinar, John Rountree, Managing Partner at Novasecta, was joined by a panel of pharma company R&D Heads, who shared their experiences on how they have been […]
Reimagine Pharma’s Commercial Model
Digitisation has already impacted, and will continue to transform, how pharma’s commercial teams interact with healthcare professionals, engage with patients, and evolve their salesforce. The COVID-19 pandemic has accelerated the previously incremental steps of digitisation for commercial teams. During lockdown, it became much more difficult for salespeople to access physicians in person – this has […]
Reimagine Medical Affairs
Medical Affairs has traditionally been an under-represented function in pharmaceutical decision-making. Yet more recently leading pharmaceutical companies have started to make much better use of Medical Affairs’ ability to understand and amplify the patient voice, resulting in higher quality R&D and Commercial decision-making. In this webinar, Andrew Bell of Novasecta was joined by Jill Massey […]